Literature DB >> 7781595

FXR1, an autosomal homolog of the fragile X mental retardation gene.

M C Siomi1, H Siomi, W H Sauer, S Srinivasan, R L Nussbaum, G Dreyfuss.   

Abstract

Fragile X mental retardation syndrome, the most common cause of hereditary mental retardation, is directly associated with the FMR1 gene at Xq27.3. FMR1 encodes an RNA binding protein and the syndrome results from lack of expression of FMR1 or expression of a mutant protein that is impaired in RNA binding. We found a novel gene, FXR1, that is highly homologous to FMR1 and located on chromosome 12 at 12q13. FXR1 encodes a protein which, like FMR1, contains two KH domains and is highly conserved in vertebrates. The 3' untranslated regions (3'UTRs) of the human and Xenopus laevis FXR1 mRNAs are strikingly conserved (approximately 90% identity), suggesting conservation of an important function. The KH domains of FXR1 and FMR1 are almost identical, and the two proteins have similar RNA binding properties in vitro. However, FXR1 and FMR1 have very different carboxy-termini. FXR1 and FMR1 are expressed in many tissues, and both proteins, which are cytoplasmic, can be expressed in the same cells. Interestingly, cells from a fragile X patient that do not have any detectable FMR1 express normal levels of FXR1. These findings demonstrate that FMR1 and FXR1 are members of a gene family and suggest a biological role for FXR1 that is related to that of FMR1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781595      PMCID: PMC398353          DOI: 10.1002/j.1460-2075.1995.tb07237.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  Cytoplasmic regulation of mRNA function: the importance of the 3' untranslated region.

Authors:  R J Jackson
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

2.  Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain.

Authors:  M Abitbol; C Menini; A L Delezoide; T Rhyner; M Vekemans; J Mallet
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

Review 3.  mRNA translation: influence of the 5' and 3' untranslated regions.

Authors:  N Sonenberg
Journal:  Curr Opin Genet Dev       Date:  1994-04       Impact factor: 5.578

Review 4.  Conserved structures and diversity of functions of RNA-binding proteins.

Authors:  C G Burd; G Dreyfuss
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

5.  The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.

Authors:  D Devys; Y Lutz; N Rouyer; J P Bellocq; J L Mandel
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  FMR1 protein: conserved RNP family domains and selective RNA binding.

Authors:  C T Ashley; K D Wilkinson; D Reines; S T Warren
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

7.  The pre-mRNA binding K protein contains a novel evolutionarily conserved motif.

Authors:  H Siomi; M J Matunis; W M Michael; G Dreyfuss
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

8.  Absence of expression of the FMR-1 gene in fragile X syndrome.

Authors:  M Pieretti; F P Zhang; Y H Fu; S T Warren; B A Oostra; C T Caskey; D L Nelson
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities.

Authors:  M S Swanson; G Dreyfuss
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  Alternative splicing in the fragile X gene FMR1.

Authors:  A J Verkerk; E de Graaff; K De Boulle; E E Eichler; D S Konecki; E Reyniers; A Manca; A Poustka; P J Willems; D L Nelson
Journal:  Hum Mol Genet       Date:  1993-04       Impact factor: 6.150

View more
  77 in total

Review 1.  Candidate RNA-binding proteins regulating extrasomatic mRNA targeting and translation in mammalian neurons.

Authors:  Stefan Kindler; Michaela Monshausen
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

2.  Exploring the zebra finch Taeniopygia guttata as a novel animal model for the speech-language deficit of fragile X syndrome.

Authors:  Claudia Winograd; Stephanie Ceman
Journal:  Results Probl Cell Differ       Date:  2012

3.  Molecular and genetic analysis of the Drosophila model of fragile X syndrome.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Results Probl Cell Differ       Date:  2012

Review 4.  The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Mol Neurobiol       Date:  2009-02-12       Impact factor: 5.590

5.  In vitro genetic analysis of the RNA binding site of vigilin, a multi-KH-domain protein.

Authors:  H Kanamori; R E Dodson; D J Shapiro
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

6.  Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes.

Authors:  Y Feng; C A Gutekunst; D E Eberhart; H Yi; S T Warren; S M Hersch
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

7.  The FRAXE Syndrome: is it time for routine screening?

Authors:  W T Brown
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

8.  Activity-dependent modulation of neural circuit synaptic connectivity.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Front Mol Neurosci       Date:  2009-07-30       Impact factor: 5.639

9.  Discrimination of common and unique RNA-binding activities among Fragile X mental retardation protein paralogs.

Authors:  Jennifer C Darnell; Claire E Fraser; Olga Mostovetsky; Robert B Darnell
Journal:  Hum Mol Genet       Date:  2009-06-01       Impact factor: 6.150

10.  Temporal requirements of the fragile x mental retardation protein in modulating circadian clock circuit synaptic architecture.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Front Neural Circuits       Date:  2009-08-20       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.